Press release from Companies

Publicerat: 2019-05-27 08:20:48

Scandion Oncology: Interim report 1 January - 31 March 2019

Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes the Interim report for the period 1 January – 31 March 2019. The interim report is available on the Company"s website (www.scandiononcology.com). Below is a summary of the report.

Reporting period January – March 2019

  •  Net sales amounted to 0 DKK (0).
  •  Operating profit was -2.345m DKK (-695).
  •  Cash and bank assets amounted to 5.281m DKK (870).
  •  Result per share was DKK -0.16 (-0.07).
  •  Solidity was 92% (66).

Highlights during the period

  • Scandion Oncology signed contract with Solural Pharma to formulate SCO-101 tablets for Clinical Phase II trial.
  • Scandion Oncology reported successful meeting with Danish Medicines Agency regarding clinical development of SCO-101. 
  • Scandion Oncology obtained Positive Preclinical Results in Antibiotic Resistance.

Highlights after the period

  • Scandion Oncology obtained EU Funding (SME Instruments Phase 1) for SCO-101 in drug resistant breast cancer patients.
  • Scandion Oncology signed collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistance.
  • Scandion Oncology received an “Intention to Grant” notice from the European Patent Office regarding its patent application covering SCO-101 in combination with specific topoisomerase I inhibitors to treat various cancers

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.

Läs mer hos Cision
Läs mer om Scandion Oncology

Utskick från Spotlight Group